Clinical Study

A Phase 2 Study To Evaluate The Safety And Effect Of Study Drug On Proteinuria In Subjects With Iga Nephropathy, Lupus Nephritis, Membranous Nephropa

Posted Date: May 15, 2019

  • Investigator: Mahmoud El-Khatib
  • Specialties:
  • Type of Study: Drug

The purpose of this study is to test the safety and describe the effect of OMS721, an ?investigational drug?, in people with these types of kidney diseases or glomerulonephropathies. ?Investigational drug? means that the drug has not been approved for sale in the United States by the U.S. Food and

Criteria:

You Are Being Asked To Consider Being In This Study Because You Have One Of These Specific Types Of

Keywords:

Membranous Nephropat, Proteinuria, Lupus Nephritis, C3 Glomerulopathy, Iga Nephropathy

For More Information:

Karen Case
(513) 559-3367
karen.case@uc.edu


  • This contact page is monitored Monday – Friday during business hours, 8 am to 5 pm EST. Do not rely on communication through this website for medical treatment or care. This website is not designed for such purposes.
    For questions regarding clinical studies at UC Health, contact us at ResearchStudies@UCHealth.com or (513) 245-3417.